The U.S. Pharmacopeia (USP) is pleased to announce the newly appointed members of the USP Council of the Convention (CoC), who will serve from 2025 to 2030. These leaders bring deep expertise; local, regional, and global perspectives; and a shared commitment to advancing the supply of quality of medicines, and the quality of dietary supplements and food ingredients for people everywhere.
Appointed by USP Convention President Hanan Sboul in consultation with USP CEO Ron Piervincenzi and approved by the USP Board of Trustees, the CoC comprises representatives of the USP Convention Membership—a dynamic community of over 450 organizations from 50 countries, offering a wide range of perspectives on the most important healthcare topics facing the world today including the resilience of the medicines supply chain, reducing drug shortages, expanding the availability of biologic medicines, and helping to ensure the quality of medicines, dietary supplements and food ingredients through USP standards.
The USP Convention serves as one of USP’s three volunteer leadership bodies, along with the USP Board of Trustees and USP Council of Experts. Throughout each five-year cycle, the CoC represents the full Convention by sharing a wide range of perspectives with USP, guiding the engagement of the Convention Membership, and making important decisions that ensure good governance and accountability while also contributing to USP’s impact. Specifically, the CoC will help ensure accountability for execution on the Resolutions adopted at the USP Convention Meeting in May 2025.
The CoC Membership for 2025-2030 includes:
Convention President and CoC Chair
- Hanan Sboul
Patient Organizations and Disease Groups
- Obesity Action Coalition, Joe Nadglowski
- Friends of Cancer Research, Jeff Allen
- National Health Council, Randy Rutta
Industry Organizations
- Association for Accessible Medicines, Giuseppe Randazzo
- National Council for Prescription Drug Programs, Steve Mullenix
- Healthcare Distribution Alliance, Nicolette Louissaint
- Healthcare Supply Chain Association, Angie Boliver
Healthcare Practitioner Groups
- Academy of Managed Care Pharmacy, Susan Cantrell
- American Pharmacists Association, Michael Hogue
- American Society of Health-System Pharmacists, Kasey Thompson
Academia
- University of Minnesota College of Pharmacy, Steve Schondelmeyer
- Howard College of Pharmacy, Ranti Akiyode
- American Association of Colleges of Pharmacy, Lynette Bradley-Baker
International Representation
- Latin America: Argentine Association of Industrial Pharmacy and Biochemistry, Federico Montes de Oca
- Europe: International Pharmaceutical Federation (FIP), Catherine Duggan
- Asia Pacific: Australia Therapeutic Goods Administration, Paul Huleatt
- South Asia: Indian Pharmaceutical Alliance, Rajiv Desai
- Africa: South African Health Products Regulatory Authority, Boitumelo Semete
U.S. Regulatory Agencies
- FDA CDER, Pallavi Nithyanandan
- National Association of Boards of Pharmacy, Al Carter
Council of Experts
- Kenneth Miller, Biologics – Therapeutic Proteins
- Ed Tidswell, Microbiology
- Allan Bokser, Small Molecules Therapeutic Area 6
- Lili Belcastro, Biologics – Cell and Gene Therapies
Guided by Science, Strengthened by Collaboration
For more than 200 years, USP has set the standard for the quality of medicines. What began in 1820 as a small gathering of physicians determined to ensure patients received the right medicines has grown into a global endeavor—one that continues to protect people’s health through science, collaboration and trust.
At the heart of this work is the USP Convention and its guiding body, the CoC. Bringing together leaders from healthcare, science, government and industry, the CoC elevates emerging issues, shares critical insights, and ensures Convention Members’ voices are reflected in USP’s work.
The Convention and CoC play a critical role in helping USP ensure our standards evolve to meet the real-world needs of patients, practitioners, regulators, and manufacturers across rapidly evolving healthcare and pharmaceutical landscapes.
USP’s ability to lead in medicines quality is powered by a unique combination of scientific rigor and stakeholder collaboration. Through expert input, regulatory and industry insights, and the work of USP’s global laboratories and in-house scientists, USP supports the development, manufacturing, and distribution of quality medicines and therapies.
As we look to the future, I’m confident that the leadership of the CoC will help USP continue to deliver on its mission—setting the standard for quality, and building trust in the quality of medicines, dietary supplements and food ingredients people rely on every day.
